GBM or DIPG – This is how ONC201 can be obtained as compassion
Intended for recurrent Glioblastoma, GBM, patients or patients with DIPG brain tumor with H3 K27M mutation We will be happy to help you access the
Pancreatic cancer – Keep reading Earl Groce’s success with CPI-613
No sign of cancer! Groce has been a part of a clinical trial since his diagnosis four-plus years ago and the results have been tremendous
Non-Small Cell Lung Cancer, NSCLC, patients with RET+ tumors – meet Pralsetinib
Background The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and
Triple Negative Breast Cancer patients – Capivasertib helps you survive
PURPOSE OF THE STUDY The trial was designed to evaluate the safety and efficacy of adding Capivasertib to Taxol as first-line therapy for metastatic TNBC
Recurrent Metastatic Head and Neck Squamous Cell Carcinoma and Salivary Gland Cancer – Two approved drugs demonstrated promising efficacy
Background This phase II trial was designed to evaluate the benefit of Keytruda® plus Zolinza® for recurrent Head and Neck Squamous Cell Carcinoma, HNSCC and
Tremelimumab in Advanced Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy
Background Urothelial cancer accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra. Tremelimumab is an
Metastatic colorectal cancer – Tumor location, left or right, impacts efficacy in KRAS/RAS wild-type patients
Background Metastatic colorectal cancer, mCRC, is a group of distinct diseases, with clinical and molecular differences between right-sided and left-sided tumors driving varying prognosis. Patients
HER2 breast cancer patients! 6% complete remission 54.9% shrinkage with Trastuzumab Deruxtecan, DS-8201
When was it reported? The outcome of the phase II, multicenter, open-label, single-arm DESTINY-Breast trial was reported at the 2019 San Antonio Breast Cancer Symposium,
Combination of Two FDA Approved Drugs Shows Promise in BRAF V600E‒Mutated Glioma
In short The results of a phase II trial in patients with BRAF V600E mutations in high- and low-grade glioma, were reported at the 24th
Potential Cure of recurrent GBM with the Oncolytic Herpes Virus G47∆
Interim results The virus has been designated a breakthrough therapy in Japan. An interim analysis of a trial of the oncolytic herpes virus G47∆ has
Glioblastoma Moltiforme, GBM – NEW immunotherapies stop from growing in newly diagnosed patients
Background According to interim findings of a phase II trial, the combination of INO-5401, a T-cell–activating immunotherapy and INO-9012, an immune activator of a different
New anti-cancer drug, Tucatinib, reduces risk of death in metastatic HER2+ breast cancer
Background There is significant unmet medical need following treatment with Herceptin, Perjeta and Kadcyla in patients with metastatic HER2-positive breast cancer. In the HER2CLIMB trial,
